Abstract
Genetically engineered mouse models (GEMM) of glioblastoma multiforme (GBM) provide a system in which de novo tumors arise and develop within the context of a proper tumor microenvironment. These models are considered superior to orthotopic xenograft systems because they allow for the development of tumors in situ and in an immune competent environment. More importantly, they allow for the assessment of specific genetic mutations on the etiology of GBM and their responses to therapeutic interventions. Using cutting edge Cre/Lox technologies, we created compound conditional transgenic strains based on a Cre-induced expression of mutant EGFRvIII with the concomitant loss of the Cdkn2a and PTEN tumor suppressor genes. The introduction of a conditional firefly luciferase transgene provides a means to monitor tumor initiation and growth noninvasively by bioluminescence imaging. The tumors that are generated in this model share numerous histopathological features with human GBMs. We provide here a detailed description of the methodologies used to initiate and monitor GBM tumors in this model system.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Wen PY, Kesari S (2008) Malignant gliomas in adults. N Engl J Med 359:492–507
Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, Scheithauer BW, Kleihues P (2007) The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 114:97–109
Huse JT, Holland EC (2010) Targeting brain cancer: advances in the molecular pathology of malignant glioma and medulloblastoma. Nat Rev Cancer 10:319–331
The Cancer Genome Atlas Network (2008) Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455:1061–1068
Verhaak RG, Hoadley KA, Purdom E, Wang V, Qi Y, Wilkerson MD, Miller CR, Ding L, Golub T, Mesirov JP, Alexe G, Lawrence M, O’Kelly M, Tamayo P, Weir BA, Gabriel S, Winckler W, Gupta S, Jakkula L, Feiler HS, Hodgson JG, James CD, Sarkaria JN, Brennan C, Kahn A, Spellman PT, Wilson RK, Speed TP, Gray JW, Meyerson M, Getz G, Perou CM, Hayes DN (2010) Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 17:98–110
Phillips HS, Kharbanda S, Chen R, Forrest WF, Soriano RH, Wu TD, Misra A, Nigro JM, Colman H, Soroceanu L, Williams PM, Modrusan Z, Feuerstein BG, Aldape K (2006) Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell 9:157–173
Frederick L, Wang XY, Eley G, James CD (2000) Diversity and frequency of epidermal growth factor receptor mutations in human glioblastomas. Cancer Res 60:1383–1387
Wong AJ, Ruppert JM, Bigner SH, Grzeschik CH, Humphrey PA, Bigner DS, Vogelstein B (1992) Structural alterations of the epidermal growth factor receptor gene in human gliomas. Proc Natl Acad Sci U S A 89:2965–2969
Inda MM, Bonavia R, Mukasa A, Narita Y, Sah DW, Vandenberg S, Brennan C, Johns TG, Bachoo R, Hadwiger P, Tan P, Depinho RA, Cavenee W, Furnari F (2010) Tumor heterogeneity is an active process maintained by a mutant EGFR-induced cytokine circuit in glioblastoma. Genes Dev 24:1731–1745
Huang PH, Xu AM, White FM (2009) Oncogenic EGFR signaling networks in glioma. Sci Signal 2:re6
Zhu H, Acquaviva J, Ramachandran P, Boskovitz A, Woolfenden S, Pfannl R, Bronson RT, Chen JW, Weissleder R, Housman DE, Charest A (2009) Oncogenic EGFR signaling cooperates with loss of tumor suppressor gene functions in gliomagenesis. Proc Natl Acad Sci USA 106:2712–2716
Serrano M, Hannon GJ, Beach D (1993) A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature 366:704–707
Zhang Y, Xiong Y, Yarbrough WG (1998) ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways. Cell 92:725–734
Lino MM, Merlo A (2010) PI3Kinase signaling in glioblastoma. J Neurooncol 103(3):417–427
Hambardzumyan D, Parada LF, Holland EC, Charest A (2011) Genetic modeling of gliomas in mice: new tools to tackle old problems. Glia 59(8):1155–1168
Gopinathan A, Tuveson DA (2008) The use of GEM models for experimental cancer therapeutics. Dis Model Mech 1:83–86
Woolfenden S, Zhu H, Charest A (2009) A Cre/LoxP conditional luciferase reporter transgenic mouse for bioluminescence monitoring of tumorigenesis. Genesis 47:659–666
Serrano M, Lee H, Chin L, Cordon-Cardo C, Beach D, DePinho RA (1996) Role of the INK4a locus in tumor suppression and cell mortality. Cell 85:27–37
Lesche R, Groszer M, Gao J, Wang Y, Messing A, Sun H, Liu X, Wu H (2002) Cre/loxP-mediated inactivation of the murine Pten tumor suppressor gene. Genesis 32:148–149
Acknowledgment
We thank Hyun Jung Jun for technical advices.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2012 Springer Science+Business Media, LLC
About this protocol
Cite this protocol
Lessard, J., Charest, A. (2012). EGFR and Tumor Suppressor Function in Brain Cancer Development. In: MartÃnez Murillo, R., MartÃnez, A. (eds) Animal Models of Brain Tumors. Neuromethods, vol 77. Humana Press, Totowa, NJ. https://doi.org/10.1007/7657_2011_30
Download citation
DOI: https://doi.org/10.1007/7657_2011_30
Published:
Publisher Name: Humana Press, Totowa, NJ
Print ISBN: 978-1-62703-208-7
Online ISBN: 978-1-62703-209-4
eBook Packages: Springer Protocols